摘要
目的:探讨Elesclomol(STA-4783)对增生性瘢痕动物模型伤口愈合中瘢痕生成的抑制作用。方法:以增生性瘢痕模型新西兰白兔为研究对象,组织学检查检测瘢痕抬高指数(SEI)、免疫组化法评价α-平滑肌肌动蛋白(α-SMA)、转化生长因子-β1(TGF-β1)、Ⅰ型和Ⅲ型胶原蛋白(CollagenⅠ和CollagenⅢ)的表达变化,TUNEL检测细胞凋亡情况。结果:给予10mmol/L浓度的Elesclomol后,与空白组动物相比,药物干预组的胶原排列由紊乱变得整齐;与对照组对比,给药组SEI由(6.27±0.43)显著降低为(2.41±0.25)(P<0.01);瘢痕横截面积由(2.17±0.22)mm^2减少到(0.92±0.14)mm^2(P<0.01);与对照组对比,药物干预组免疫组织化学分析显示TGF-β1、α-SMA、CollagenⅠ和CollagenⅢ的表达均显著降低(P<0.01);TUNEL显示细胞凋亡数由(10.9±1.8)增至(32.4±4.7)(P<0.01)。结论:Elesclomol降低兔耳增生性瘢痕胶原、α-SMA、TGF-β1蛋白的表达,促进成纤维细胞凋亡,对兔耳增生性瘢痕的形成具有明显的抑制作用。
AIM:To observe the effects of Elesclomol(STA-4783)on hypertrophic scar formation in rabbit ears.METHODS:Newborn white rabbits with hypertrophic scar model were used as subjects.Histological examination was used to detect scar elevation index(SEI),and immunohistochemical method was used to evaluateα-smooth muscle actin(α-SMA)and transforming growth factor-β1(TGF-β1),type I and type III collagen(Collagen I and Collagen III)expression changes and Tunel detects apoptosis in cells.RESULTS:After administration of Elesclomol at a concentration of 10 mmol/L,the collagen arrangement of the drug-treated group was neglected from the disorder compared with the model group.Compared with the control group,the SEI of the drug-administered group was significantly reduced from(6.27±0.43)to(2.41±0.25)(P<0.01);the cross-sectional area of the scar was reduced from(2.17±0.22)mm 2 to(0.92±0.14)mm 2(P<0.01);compared with the control group,immunohistochemical analysis of the drug intervention group showed TGF-β1,α-SMA,Collagen I and Collagen III.The expression was significantly decreased(P<0.01);Tunel showed that the number of apoptosis increased from(10.9±1.8)to(32.4±4.7)(P<0.01).CONCLUSION:Elesclomol reduces the expressions of TGF-β1,α-SMA,Collagen I and Collagen II and increases the apoptosis of fibroblasts,which indiates Elesclomol has a significant inhibitory effect on hypertrophic scars in rabbit ears.
作者
冯艺
孙子荔
杜勇
俞舜
杨敏烈
吕国忠
许正新
袁凤来
FENG Yi;SUN Zili;DU Yong;YU Shun;YANG Minlie;LV Guozhong;XU Zhengxin;YUAN Fenglai(Department of Pharmacology,Medical School,Yangzhou University,Yangzhou 225000,Jiangsu,China;Department of Orthopaedics and Central Laboratory,the Third Hospital Affiliated to Nantong University,Wuxi 214041,Jiangsu,China;Department of Orthopaedics and Central Laboratory,the Hospital Affiliated to Jiangnan University,Wuxi 214041,Jiangsu,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2019年第8期860-865,共6页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金面上项目(81671912)
江苏省社会发展项目(BE2018626)